NUMANS Health Food Holdings Limited, once hailed by the market as the "NONGFU SPRING of the mother and baby sector," is now mired in a crisis of confidence in the capital markets. This dietary supplement company, which listed on the Hong Kong Stock Exchange in early 2025, is confronting multiple challenges just over a year after its IPO, including dried-up liquidity, a stock price persistently below its offering price, and instability among key senior management. With its former auditor resigning over a fee dispute and the statutory deadline for publishing its annual results for the new fiscal year less than a month away, NUMANS is on the brink of potential compulsory trading suspension.
Since its debut on the Hong Kong stock market in January 2025, NUMANS's stock performance has disappointed early investors. Data shows that as of the market close on March 5, 2026, NUMANS's share price stood at HKD 0.590, with a daily turnover of just HKD 300,000 and a turnover rate as low as 0.05%. The stock's 52-week high was HKD 0.893, while its low touched HKD 0.500, remaining well below its initial public offering price. Even news on March 4th that the company had spent HKD 19.73 million to acquire 2 million shares of Jingtai Technology prompted only a minimal 1.724% price increase, indicating a highly tepid market response. On some trading days, there were no transactions recorded at all, or volume amounted to only a few thousand shares, a typical state for a so-called "zombie stock."
A more immediate concern for the market is a sudden disruption in the company's financial information disclosure. On March 3, NUMANS announced that its former auditor, Crowe HK CPA Limited, had resigned effective immediately. The Board subsequently appointed Ferrier Mažars CPA Limited as the new auditor until the conclusion of the next annual general meeting. In a subsequent announcement, the company disclosed that Crowe HK resigned because the two parties "failed to reach a consensus on the adjustment of audit fees." This seemingly routine disagreement over professional service fees, occurring just before the critical deadline for annual results publication, has been interpreted by the market as a significant negative signal.
The last-minute change of auditors has directly led to a delay in publishing the annual results. NUMANS confirmed in its March 3 announcement that it would be unable to publish its 2025 annual results by March 31, 2026, as required, and expects to complete the process by April 30, 2026, at the latest. This means that with less than a month until the statutory deadline, the audit process effectively had to restart. The announcement detailed several factors impeding audit progress: changes in key financial personnel at a major subsidiary delayed the preparation and provision of financial information, particularly extending the time needed to obtain opening balance data; financial and other department staff were heavily occupied with new product launch activities in Q4 2025, reducing their availability for in-depth discussions; and specific pending audit issues related to opening inventory, opening contract assets, and income tax provisions required clarification.
Under HKEX listing rules, the exchange typically has the authority to require a trading suspension if an issuer fails to publish periodic financial reports on time. Although NUMANS's board anticipates completing the results publication by April 30, the feasibility of this timeline remains highly uncertain given that the audit has not substantially recommenced, core financial staff have changed, and multiple audit matters are unresolved. If the company fails to publish the annual results by March 31 without obtaining an exemption from the exchange, its shares will face compulsory suspension until the financial statements are issued. For NUMANS, which already suffers from extremely low trading activity, a suspension would undoubtedly exacerbate difficulties for investors seeking to exit and would severely damage the company's public image.
NUMANS primarily engages in the sale of dietary nutrition supplements, targeting the mother and baby market with algae oil DHA as its flagship product. Before its listing, the company was dubbed the "NONGFU SPRING of the mother and baby sector" due to its deep penetration in maternal and infant channels and the recognition of its "NUMANS" brand. However, its performance over the past year has fallen far short of this accolade. Beyond the dismal secondary market performance, underlying weaknesses in the company's fundamentals have gradually emerged. Interim results for the period ended June 30, 2025, revealed revenue of RMB 93.156 million, a significant year-on-year decrease of 36.23%, and a net profit of just RMB 2.129 million, a dramatic plunge of 95.30%, indicating extremely weak profitability. Persistent issues such as high sales expenses, a narrow product portfolio, and ineffective expansion into new businesses have remained unresolved.
Analysis suggests that in an intensely competitive mother and baby sector with rapidly shifting consumer preferences, NUMANS, which relies heavily on a single DHA product, is facing a growth ceiling. Furthermore, the company's recent investment of nearly HKD 20 million to acquire a stake in Jingtai Technology has been questioned by some investors as a distraction from its core business. Now, with the simultaneous eruption of three major crises—auditor resignation, delayed annual results, and liquidity drought—NUMANS is facing its darkest hour since going public. Time is running out for this former "star stock" of the mother and baby sector.
Comments